Valuation: Replimune Group, Inc.

Capitalization 388M 335M 307M 290M 534M 37.57B 548M 3.65B 1.42B 17.69B 1.46B 1.43B 61.76B P/E ratio 2026 *
-1.4x
P/E ratio 2027 * -2.42x
Enterprise value 269M 232M 213M 201M 370M 26.05B 380M 2.53B 987M 12.26B 1.01B 988M 42.83B EV / Sales 2026 *
-
EV / Sales 2027 * 103x
Free-Float
97.28%
Yield 2026 *
-
Yield 2027 * -
1 day-6.19%
1 week+14.91%
Current month+82.88%
1 month+116.59%
3 months-45.03%
6 months-47.72%
Current year-51.65%
1 week 4.5
Extreme 4.5
5.54
1 month 1.84
Extreme 1.8425
5.54
Current year 1.5
Extreme 1.5
9.77
1 year 1.5
Extreme 1.5
13.24
3 years 1.5
Extreme 1.5
24.81
5 years 1.5
Extreme 1.5
40.22
10 years 1.5
Extreme 1.5
54.85
Manager TitleAgeSince
Chief Executive Officer 55 01/04/2024
Director of Finance/CFO 46 19/09/2023
Chief Tech/Sci/R&D Officer 60 01/12/2022
Director TitleAgeSince
Chairman 54 01/04/2024
Director/Board Member 66 01/07/2017
Chairman 65 01/04/2020
Change 5d. change 1-year change 3-years change Capi.($)
-6.19%+14.91%-42.68%-76.00% 388M
+0.12%+3.08%-13.36%-15.32% 43.14B
+1.34%-5.73%+27.27%+27.69% 33.02B
+2.03%+1.08%+268.90%+469.83% 31.32B
+0.21%-1.07%+20.65%-13.17% 28.9B
-0.38%-5.59%+23.25%+14.60% 25.34B
+0.14%+0.14% - - 14.78B
-2.84%+2.47%+191.46%+4,084.10% 13.35B
+0.07%+4.28%+7.77%+1.05% 12.5B
-0.18%+0.04%+37.23%+99.12% 11.99B
Average -0.57%+1.33%+57.83%+510.21% 21.47B
Weighted average by Cap. +0.32%-0.55%+65.08%+353.36%

Financials

2026 *2027 *
Net sales - 3.14M 2.71M 2.48M 2.34M 4.32M 304M 4.43M 29.54M 11.5M 143M 11.77M 11.52M 499M
Net income -310M -267M -245M -231M -427M -30.01B -437M -2.92B -1.14B -14.13B -1.16B -1.14B -49.33B -210M -181M -166M -157M -289M -20.3B -296M -1.97B -769M -9.55B -787M -770M -33.36B
Net Debt -119M -103M -94.02M -88.84M -164M -11.52B -168M -1.12B -436M -5.42B -447M -437M -18.94B -63.5M -54.77M -50.17M -47.41M -87.4M -6.15B -89.6M -598M -233M -2.89B -238M -233M -10.11B
Logo Replimune Group, Inc.
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
Employees
479
Date Price Change Volume
19/05/26 4.700 $ -6.19% 4,542,262
18/05/26 5.010 $ -4.02% 5,118,010
15/05/26 5.220 $ +5.88% 5,875,124
14/05/26 4.930 $ -6.98% 9,285,307
13/05/26 5.300 $ +29.58% 17,769,335
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
4.700USD
Average target price
3.500USD
Spread / Average Target
-25.53%

Quarterly revenue - Rate of surprise